Testimony of James L. Mohler, MD Before the Senate Committee on Foreign Relations The Al-Megrahi Release: One Year Later

Expert opinion about the “three months to live” prognosis Scottish physicians gave Abdelbaset Ali Mohmed al-Megrahi in August 2009. September 29, 2010 “Based on the medical report issued by the Scottish authorities, I believe that three-month prognosis was medically unjustifiable. Any physician with any training or experience in treating prostate cancer would have known that [...]

Androgen deprivation therapy for prostate cancer: Recommendations to improve patient and partner quality of life

Written by our own Richard Wassersug appearing in UroToday.com BERKELEY, CA (UroToday.com) – Much has happened with the use of androgen deprivation to treat prostate cancer (PCa) patients since Charles Huggins first castrated a patient in order to alleviate the symptoms of advanced PCa. Back then, patients were generally elderly and symptomatic with either urethral [...]

Sodium Clodronate Improves Survival In Patients With Advanced Prostate Cancer But Not With Localized Disease

An article published Online First and in an upcoming edition of The Lancet Oncology reports that an oral bisphosphonate, sodium clodronate, improves overall survival in men with advanced prostate cancer. However, it does not reduce the risk of death in men with localized disease. These are the final results of the MRC PR05 and MRC [...]

Neuroendocrine Prostate Cancer – A Tough Disease To Treat

We are finding that there are many different types of prostate cancer, all of them are actually different diseases. At Memorial Sloane Kettering Hospital, New York City, they recently announced that, based on genetic analysis, they have identified 23 different types of prostate cancer. One of these cancer types is neuroendocrine prostate cancer which is [...]

Go to Top